Santos Ana M R, Pomin Vitor H, Stelling Mariana P, Guimarães Marco A M, Cardoso Lucio R, Mourão Paulo A S
Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Caixa Postal 68041, Rio de Janeiro, RJ, 21941-590, Brazil.
Clin Chim Acta. 2007 Aug;383(1-2):116-25. doi: 10.1016/j.cca.2007.05.013. Epub 2007 May 26.
Puromycin aminonucleoside-induced nephrosis is characterized by increased renal excretion of plasma proteins. We employed this experimental model to study the urinary clearance of dextran sulfate.
The dextran sulfate eliminated by the urine was determined using a metachromatic assay. Polysaccharide fragments were analyzed by chromatographic and electrophoretic procedures. Disaccharide composition of the glomerular heparan sulfate was assessed using digestion with specific lyases.
In normal rats dextran sulfate is partially degraded to lower molecular weight fragments and only then eliminated by the urine. Surprisingly, in puromycin aminonucleoside-induced glomerulosclerosis the molecular size of the fragments of dextran sulfate found in the urine is the same or even lower than in control animals in spite of the marked proteinuria. Furthermore, urinary excretion of dextran sulfate decreases in the experimentally induced nephrosis. This observation cannot be totally attributed to a reduced number of physiologically active nephrons since the glomerular filtration rate decreases approximately 32% after puromycin aminonucleoside administration while the urinary excretion of 8 kDa-dextran sulfate decreases 3-fold. The glomerular heparan sulfate shows reduced sulfation when compared with normal animals. Possibly puromycin aminonucleoside decreases the activity of kidney endoglycosidases, which reduce the molecular size of the sulfated polysaccharide, leading to a decrease in its renal clearance. Reduced sulfation of the glomerular heparan sulfate in the puromycin aminonucleoside-induced nephrosis does not alter the size of the dextran sulfate eliminated by the kidney, as suggested for protein.
Each pathological process induces a particular modification in the kidney, which in turn can affect the renal selectivity to specific macromolecules in different ways.
嘌呤霉素氨基核苷诱导的肾病的特征是血浆蛋白的肾排泄增加。我们采用这个实验模型来研究硫酸葡聚糖的尿清除率。
用变色测定法测定经尿液排出的硫酸葡聚糖。通过色谱和电泳程序分析多糖片段。用特异性裂解酶消化来评估肾小球硫酸乙酰肝素的二糖组成。
在正常大鼠中,硫酸葡聚糖部分降解为低分子量片段,然后才经尿液排出。令人惊讶的是,在嘌呤霉素氨基核苷诱导的肾小球硬化症中,尽管存在明显的蛋白尿,但尿液中发现的硫酸葡聚糖片段的分子大小与对照动物相同甚至更低。此外,在实验性诱导的肾病中硫酸葡聚糖的尿排泄减少。这一观察结果不能完全归因于生理活性肾单位数量的减少,因为在给予嘌呤霉素氨基核苷后肾小球滤过率降低约32%,而8 kDa硫酸葡聚糖的尿排泄减少了3倍。与正常动物相比,肾小球硫酸乙酰肝素的硫酸化程度降低。嘌呤霉素氨基核苷可能降低了肾脏内切糖苷酶的活性,该酶会减小硫酸化多糖的分子大小,导致其肾清除率降低。在嘌呤霉素氨基核苷诱导的肾病中,肾小球硫酸乙酰肝素硫酸化程度的降低并未改变肾脏排出的硫酸葡聚糖的大小,这与蛋白质的情况不同。
每个病理过程都会在肾脏中引发特定的改变,进而可能以不同方式影响肾脏对特定大分子的选择性。